Sanofi Starts Selling Diabetes Treatment Soliqua in U.S.

   By Inti Landauro 
 

PARIS--French drug giant Sanofi SA (SAN.FR) said Wednesday it started selling in the U.S. a new diabetes treatment called Soliqua, a combination of drugs glargine and lixisenatide, as part of efforts to offset an expected decline in revenue from the loss of patent protection for its Lantus insulin treatment.

The new treatment has demonstrated more efficiency than Lantus, Sanofi said.

Soliqua is a combination of two drugs already on the market, including Lantus. Sanofi says a single daily dose of the mix will allow a patient to improve the control of glycemia level.

The new treatment was approved by the U.S. Food and Drug Administration late last year.

Sanofi is one of the world's largest maker of diabetes drugs, though its business is under pressure as health-care systems get more cost-conscious and competition increases.

Write to Inti Landauro at [e-mail]

(END) Dow Jones Newswires

January 04, 2017 01:59 ET (06:59 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.